the Promise of MicroRNA Biomarkers

Researchers have identified a specific group of microRNAs (miRNAs) as reliable
[2]
[3]
[1]

biomarkers for detecting malignant testicular germ cell tumors (TGCTs), the most prevalent solid cancer affecting young men. This breakthrough offers the potential for earlier adn less invasive cancer diagnosis.

The Cornell University research team’s findings suggest that these biomarkers could even facilitate prenatal diagnosis. The study,detailed in Scientific Reports,demonstrates the specificity of certain miRNAs in regulating gene expression within TGCTs,using a mouse model.Notably, the identified miRNA has a human equivalent, bolstering its viability as a precise diagnostic tool.

Liquid Biopsy: A Paradigm Shift in Cancer Diagnostics

The field of cancer diagnostics is increasingly embracing less invasive methods, with liquid biopsy at the forefront. According to Robert Weiss, a molecular genetics professor at Cornell’s Faculty of Veterinary Medicine,

there is a big encouragement to switch to more invasive methods, such as liquid biopsy.
Robert Weiss, Cornell University

Liquid biopsy enables disease detection, recurrence monitoring post-surgery, and even early screening through simple blood samples. This technology simplifies cancer detection, eliminating the need for complex surgical procedures.

Testicular Cancer in Young Men: Incidence and Prognosis

In the united States, TGCT is the most common cancer among men aged 15 to 39, with incidence rates climbing nearly 40% over the past half-century. Despite this, TGCT is highly responsive to conventional chemotherapy, resulting in a five-year survival rate of approximately 95%.

Unraveling the Origins and Characteristics of TGCTs

Research indicates that TGCTs originate during embryonic development and can evolve into invasive cancers, particularly after puberty. These tumors contain pluripotent cancer stem cells, capable of differentiating into various cancer cell types.

The Cornell team utilized a previously developed mouse model to investigate TGCT development. This model allows for the growth of tumor cells in a laboratory setting and the induction of cell differentiation, causing them to lose their pluripotency. This enables researchers to compare undifferentiated cancer stem cells with more specialized cells.

miRNA Mechanism: A Novel Cancer biomarker

Inspired by human clinical studies demonstrating the potential of serum miRNAs as cancer biomarkers
[1], the researchers discovered that a group of miRNAs, specifically Mirna 290-295 in mice, is exclusively expressed and secreted by undifferentiated testicular cancer cells. The human equivalent of this miRNA is the Mirna 371-373 group.

The study revealed that this miRNA is specific to malignant testicular cancer and absent in other tumors, such as breast cancer or benign testicular tumors, highlighting its accuracy as a biomarker.

Furthermore, the researchers identified the genes targeted by the miRNA and how it suppresses their expression. According to Weiss,

If we look at the function of these genes, they regulate processes related to cancer, such as cell cycles and apoptosis (cell death).
Robert Weiss, Cornell University

future Implications: miRNA-Targeted Therapies

Weiss emphasizes the meaning of mouse models in accurately representing human disease, facilitating experimentation that is challenging to conduct directly on humans. This discovery paves the way for further research into the function of miRNAs, their target genes, and their role in cancer development.

The ultimate goal is to develop miRNA-targeted therapies to halt tumor growth and spread. As Weiss concludes,

Than this can be the first step in developing therapy targeting Mirna to stop the growth or spread of tumors.
Robert Weiss, Cornell University